Trial · NCT03558919
Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
NCT03558919, Phase 4, Completed, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder. Trials, record NCT03558919. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03558919
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
- NCT number
- NCT03558919
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 81 participants, actual
- Lead sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Conditions
- Overactive Bladder
- Interventions
- Mirabegron 25mg, Solifenacin Succinate 5 MG
- First posted
- 2018-06-15
- Last updated
- 2018-06-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overactive symptom score (OABSS) | 12 weeks | Overactive bladder symptom score Patients are instructed to circle the score that best applies to their urinary condition during the past week; the overall score the sum of the four scores. Ques-1 How many times do youtypically urinate fromwaking in the morninguntil sleeping at night? Ques 2 How many times do you typically wake up to urinate from sleeping at night until waking in the morning? Ques 3 How often do you have a sudden desire to urinate, which is difficult to defer? Ques 4. How often do you leak urine because you cannot defer the sudden desire to urinate? Total score Sum of 4 question, Maximum score 15. Reduction OABSS will calculated from baseline |
| Secondary | Frequency of micturation | 12 weeks | Frequency of micturation will be reduced at end of treatment at 12 week calculated from before treatment. |
| Secondary | Urgency | 12 weeks | The percentage of patients with a change from baseline to the final visit in the urgency episodes per 24 hours by 2 or greater. |
| Secondary | Urgency incontinence | 12 weeks | Net change of the mean number of urgency incontinence episodes from baseline to the final visit |
| Secondary | Nocturia | 12 weeks | The net change of mean number of nocturia episodes per 24 hours from baselinev to the final visit |
| Secondary | Adverse effects | 12 weeks | Dry mouth, constipation, blurred vision, hypertension, haedache, nasopharyngitis. Number of participant will be developed advers effect during study period will compared between them. |
| Secondary | Discontinue drug due to adverse effect | 12 weeks | Number of participant discontinue drug due to adverse effect wil compared between them |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03558919
GET https://conductscience.org/api/trials/v1/NCT03558919/registered